iRhythm Technologies, Inc. (IRTC)
NASDAQ: IRTC · Real-Time Price · USD
177.37
+1.17 (0.66%)
Oct 13, 2025, 4:00 PM EDT - Market closed
iRhythm Technologies Revenue
iRhythm Technologies had revenue of $186.69M in the quarter ending June 30, 2025, with 26.10% growth. This brings the company's revenue in the last twelve months to $657.23M, up 22.37% year-over-year. In the year 2024, iRhythm Technologies had annual revenue of $591.84M with 20.13% growth.
Revenue (ttm)
$657.23M
Revenue Growth
+22.37%
P/S Ratio
8.51
Revenue / Employee
$328,614
Employees
2,000
Market Cap
5.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 591.84M | 99.16M | 20.13% |
| Dec 31, 2023 | 492.68M | 81.76M | 19.90% |
| Dec 31, 2022 | 410.92M | 88.10M | 27.29% |
| Dec 31, 2021 | 322.83M | 57.66M | 21.74% |
| Dec 31, 2020 | 265.17M | 50.61M | 23.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IRTC News
- 25 days ago - IRHYTHM INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. – IRTC - GlobeNewsWire
- 4 weeks ago - IRhythm Technologies, Inc. (IRTC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies' Zio LTCM Service - GlobeNewsWire
- 7 weeks ago - iRhythm Technologies to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Investor Short Report Flags Steep Downside Risk For iRhythm Technologies - Benzinga
- 2 months ago - AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm's Zio LTCM Clinical Superiority - GlobeNewsWire
- 2 months ago - iRhythm Technologies, Inc. (IRTC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - iRhythm Technologies Announces Second Quarter 2025 Financial Results - GlobeNewsWire